Longevity: Can We Add Another 30 Years? | The Decade Ahead
About this episode
This episode explores the advancements in longevity science and investment opportunities in the biotech sector.
People are living longer than ever before and the science helping us live healthier for longer is advancing at a rapid pace. From AI-powered drug discovery and personalised medicine to GLP-1s and the longevity economy, this episode explores the trends reshaping healthcare, the companies leading the charge, and how investors can gain exposure to one of the world's fastest-growing industries. In this episode: 00:00 – Why longevity is becoming a major investment theme 03:16 – The $3.5 trillion biotech opportunity & the rise of the longevity economy 07:58 – AI, peptides & personalised medicine driving medical breakthroughs 14:56 – The risks: regulation, clinical trial failures & tariffs 17:47 – Partner message from ANZ Business Start Right 19:22 – The biggest opportunities in biotech over the next decade 20:25 – The companies leading the biotech revolution 27:13 – ETFs and how to invest in Biotech & Longevity Stocks & ETFs Mentioned: CSL (ASX: CSL), Pfizer (NYSE: PFE), Merck (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Roche, AstraZeneca (LSE: AZN), AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Vertex Pharmaceuticals (NASDAQ: VRTX)…
Sponsors
ANZ Business Start Right
More episodes of Equity Mates Investing Podcast
- Entertainment: The Smartphone Is Eating Hollywood | The Decade Ahead
- Electrification: Australia’s Chance to Power the World | The Decade Ahead
- Pet Care: Australia Has More Pets Than People | The Decade Ahead
- Self-Driving Cars: From 7,000 to 6 million Robotaxis | The Decade Ahead
- Why gold fell when war broke out (and what that tells you)
- Our Monthly Portfolio Update - June 2026
Explore listener stats, chart rankings, contacts and more on the Equity Mates Investing Podcast podcast page.